vs
Side-by-side financial comparison of Enact Holdings, Inc. (ACT) and Alkermes plc. (ALKS). Click either name above to swap in a different company.
Alkermes plc. is the larger business by last-quarter revenue ($384.5M vs $312.7M, roughly 1.2× Enact Holdings, Inc.). On growth, Enact Holdings, Inc. posted the faster year-over-year revenue change (3.6% vs -10.6%). Over the past eight quarters, Alkermes plc.'s revenue compounded faster (4.8% CAGR vs 3.6%).
Enact Holdings, Inc. is a leading U.S.-based private mortgage insurance provider. It delivers risk mitigation solutions to residential mortgage lenders, banks, and credit unions, enabling borrowers with smaller down payments to access affordable home financing, and supports sustainable homeownership for diverse consumer groups across the United States.
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio.
ACT vs ALKS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $312.7M | $384.5M |
| Net Profit | — | $49.3M |
| Gross Margin | — | 88.0% |
| Operating Margin | 71.3% | 15.1% |
| Net Margin | — | 12.8% |
| Revenue YoY | 3.6% | -10.6% |
| Net Profit YoY | — | -66.3% |
| EPS (diluted) | $1.23 | $0.29 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $312.7M | $384.5M | ||
| Q3 25 | $311.5M | $394.2M | ||
| Q2 25 | $304.9M | $390.7M | ||
| Q1 25 | $306.8M | $306.5M | ||
| Q4 24 | $301.8M | $430.0M | ||
| Q3 24 | $309.6M | $378.1M | ||
| Q2 24 | $298.8M | $399.1M | ||
| Q1 24 | $291.6M | $350.4M |
| Q4 25 | — | $49.3M | ||
| Q3 25 | — | $82.8M | ||
| Q2 25 | — | $87.1M | ||
| Q1 25 | — | $22.5M | ||
| Q4 24 | — | $146.5M | ||
| Q3 24 | — | $92.4M | ||
| Q2 24 | — | $91.4M | ||
| Q1 24 | — | $36.8M |
| Q4 25 | — | 88.0% | ||
| Q3 25 | — | 86.9% | ||
| Q2 25 | — | 87.3% | ||
| Q1 25 | — | 83.9% | ||
| Q4 24 | — | 85.6% | ||
| Q3 24 | — | 83.3% | ||
| Q2 24 | — | 84.6% | ||
| Q1 24 | — | 83.3% |
| Q4 25 | 71.3% | 15.1% | ||
| Q3 25 | 67.4% | 22.6% | ||
| Q2 25 | 70.4% | 23.8% | ||
| Q1 25 | 68.9% | 4.5% | ||
| Q4 24 | 68.9% | 37.8% | ||
| Q3 24 | 74.1% | 27.7% | ||
| Q2 24 | 78.6% | 27.5% | ||
| Q1 24 | 70.6% | 12.4% |
| Q4 25 | — | 12.8% | ||
| Q3 25 | — | 21.0% | ||
| Q2 25 | — | 22.3% | ||
| Q1 25 | — | 7.3% | ||
| Q4 24 | — | 34.1% | ||
| Q3 24 | — | 24.4% | ||
| Q2 24 | — | 22.9% | ||
| Q1 24 | — | 10.5% |
| Q4 25 | $1.23 | $0.29 | ||
| Q3 25 | $1.10 | $0.49 | ||
| Q2 25 | $1.11 | $0.52 | ||
| Q1 25 | $1.08 | $0.13 | ||
| Q4 24 | $1.05 | $0.88 | ||
| Q3 24 | $1.15 | $0.55 | ||
| Q2 24 | $1.16 | $0.53 | ||
| Q1 24 | $1.01 | $0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $582.5M | $388.6M |
| Total DebtLower is stronger | $744.5M | — |
| Stockholders' EquityBook value | $5.4B | $1.8B |
| Total Assets | $6.9B | $2.5B |
| Debt / EquityLower = less leverage | 0.14× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $582.5M | $388.6M | ||
| Q3 25 | $545.6M | $616.4M | ||
| Q2 25 | $616.0M | $521.2M | ||
| Q1 25 | $639.0M | $399.8M | ||
| Q4 24 | $602.8M | $291.1M | ||
| Q3 24 | $674.9M | $396.3M | ||
| Q2 24 | $711.3M | $535.1M | ||
| Q1 24 | $624.3M | $420.8M |
| Q4 25 | $744.5M | — | ||
| Q3 25 | $744.1M | — | ||
| Q2 25 | $743.8M | — | ||
| Q1 25 | $743.4M | — | ||
| Q4 24 | $743.0M | — | ||
| Q3 24 | $742.7M | — | ||
| Q2 24 | $742.4M | — | ||
| Q1 24 | $746.1M | — |
| Q4 25 | $5.4B | $1.8B | ||
| Q3 25 | $5.3B | $1.7B | ||
| Q2 25 | $5.2B | $1.6B | ||
| Q1 25 | $5.1B | $1.5B | ||
| Q4 24 | $5.0B | $1.5B | ||
| Q3 24 | $5.0B | $1.3B | ||
| Q2 24 | $4.8B | $1.3B | ||
| Q1 24 | $4.7B | $1.3B |
| Q4 25 | $6.9B | $2.5B | ||
| Q3 25 | $6.9B | $2.3B | ||
| Q2 25 | $6.8B | $2.3B | ||
| Q1 25 | $6.7B | $2.1B | ||
| Q4 24 | $6.5B | $2.1B | ||
| Q3 24 | $6.6B | $2.2B | ||
| Q2 24 | $6.3B | $2.2B | ||
| Q1 24 | $6.3B | $2.1B |
| Q4 25 | 0.14× | — | ||
| Q3 25 | 0.14× | — | ||
| Q2 25 | 0.14× | — | ||
| Q1 25 | 0.15× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.15× | — | ||
| Q2 24 | 0.15× | — | ||
| Q1 24 | 0.16× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $724.5M | $170.1M |
| Free Cash FlowOCF − Capex | — | $170.0M |
| FCF MarginFCF / Revenue | — | 44.2% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | 3.45× |
| TTM Free Cash FlowTrailing 4 quarters | — | $480.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $724.5M | $170.1M | ||
| Q3 25 | $192.0M | $101.7M | ||
| Q2 25 | $119.5M | $150.2M | ||
| Q1 25 | $226.7M | $98.8M | ||
| Q4 24 | $686.3M | $190.4M | ||
| Q3 24 | $188.1M | $81.6M | ||
| Q2 24 | $144.7M | $146.0M | ||
| Q1 24 | $187.3M | $21.1M |
| Q4 25 | — | $170.0M | ||
| Q3 25 | — | $84.4M | ||
| Q2 25 | — | $137.2M | ||
| Q1 25 | — | $88.7M | ||
| Q4 24 | — | $180.6M | ||
| Q3 24 | — | $73.3M | ||
| Q2 24 | — | $138.9M | ||
| Q1 24 | — | $12.8M |
| Q4 25 | — | 44.2% | ||
| Q3 25 | — | 21.4% | ||
| Q2 25 | — | 35.1% | ||
| Q1 25 | — | 28.9% | ||
| Q4 24 | — | 42.0% | ||
| Q3 24 | — | 19.4% | ||
| Q2 24 | — | 34.8% | ||
| Q1 24 | — | 3.6% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 4.4% | ||
| Q2 25 | — | 3.3% | ||
| Q1 25 | — | 3.3% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 2.2% | ||
| Q2 24 | — | 1.8% | ||
| Q1 24 | — | 2.4% |
| Q4 25 | — | 3.45× | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 1.72× | ||
| Q1 25 | — | 4.40× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | — | 0.88× | ||
| Q2 24 | — | 1.60× | ||
| Q1 24 | — | 0.57× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACT
Segment breakdown not available.
ALKS
| Vivitrol | $124.1M | 32% |
| Aristada And Aristada Initio | $97.2M | 25% |
| LYBALVI | $94.1M | 24% |
| Royalty | $65.7M | 17% |
| Manufacturing Revenue | $3.3M | 1% |
